Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 548aq (MIR548AQ)
- Target
- MIR548AQ
- Molecular classification
- MicroRNA (miRNA), Non-coding RNA, Regulatory RNA
01
Overview
MicroRNA 548aq is a primate-specific, poorly conserved member of the large mir-548 family of miRNA genes. MIR548AQ is transcribed in humans as a short (20–24 nucleotide) non-coding RNA functioning to regulate gene expression post-transcriptionally by inhibiting translation or destabilizing mRNAs. Its mature strand miR-548aq-3p is implicated in modulation of angiogenic activity of ECFCs, and its expression is downregulated by far infrared radiation, with potential biomarker utility for CAD patients with CKD. The broader mir-548 family is associated with signaling processes and cancers, likely due to their roles in gene regulation. As of now, there are no characterized interacting drugs or direct therapeutic applications, but miR-548aq-3p downregulation may indicate improved response to certain non-pharmacological therapies.
- Other names
- MIR548AQhsa-mir-548aqmicroRNA 548aq
02
Mechanism of action
Not applicable; no known drugs target this microRNA.
03
Biological functions
Post-transcriptional regulation of gene expressionMay affect stability and translation of target mRNAsPossible role in angiogenesis and endothelial cell function, as miR-548aq-3p impacts tube formation in endothelial colony forming cells (ECFCs)
04
Disease associations
Potential biomarker in coronary artery disease (CAD) and chronic kidney disease (CKD), as downregulation after far infrared radiation (FIR) correlates with ECFC responsivenessGeneral miR-548 family is implicated in signaling pathways and some cancers; specific disease role for MIR548AQ remains uncharacterized, possible association through family membership.
05
Safety considerations
None documented. Challenges typical to microRNA therapies and biomarkers may include specificity, off-target effects, and delivery but are not specifically attributed to MIR548AQ
06
Biomarkers
Downregulation of miR-548aq-3p after FIR treatment in CAD and CKD patients may serve as a biomarker for therapy efficacy
Beyond the preview
Go deeper on MicroRNA 548aq (MIR548AQ).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroRNA 548aq (MIR548AQ).